Orion Corporation

Diversified pharma; originator of levosimendan

ORNBV · Nasdaq Helsinki · Finland

Public Market Listing

ORNBVNasdaq Helsinki

Nasdaq Helsinki primary exchange listing

Live quotes, historical charts, and market capitalization for Orion Corporation are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
entacapone(Comtess)
Approved
COMTSmall molecule
Parkinson's Disease
Levosimendan(Simdax)
Phase 3
Cardiac troponin C (calcium sensitizer)Small molecule
Heart FailurePulmonary Hypertension due to Left Heart Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Levosimendan · SimdaxPhase 3Pulmonary Hypertension Associated With HFpEF
Est. primary completion 2028-06-30 · NCT07288398 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Levosimendan · SimdaxPhase 3Pulmonary Hypertension Associated With HFpEF
Est. primary completion 2029-03 · NCT07436689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 August 2026Topline resultLevosimendanPhase 3 LEVEL topline: primary endpoint not met
Tenax Therapeutics · Source ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$1.4B$163M$263M—report ↗

Orion Corporation reported revenue of $1,395.54M, up 14.7% YoY, R&D spend of $163.37M, up 27.0% YoY, and cash and equivalents of $263.05M for Q3 2025.

Figures only: this period's report disclosed no narrative text

View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$842M$98M$215M—report ↗
2025-Q1$373M$43M$281M—report ↗
2024-Q3$1.2B$129M$212M—report ↗
2024-H1$689M$87M$163M—report ↗
2024-Q1$335M$40M$203M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.1B$239M$189M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.7B$194M$214M—report ↗
2023-FY$1.3B$137M$118M—report ↗
2022-FY$1.4B$143M$355M—report ↗
2021-FY$1.2B$139M$245M—report ↗